{"id":"anlotinib-blank","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Hypertension"},{"rate":"20-30","effect":"Proteinuria"},{"rate":"15-25","effect":"Hand-foot skin reaction"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Anorexia"},{"rate":"10-20","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4303201","moleculeType":"Small molecule","molecularWeight":"407.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anlotinib inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and growth signaling, including VEGFR2, FGFR1, PDGFR-β, and c-Kit. By blocking these pathways, it reduces new blood vessel formation to tumors and directly inhibits tumor cell proliferation and survival.","oneSentence":"Anlotinib is a multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor growth by inhibiting VEGFR, FGFR, PDGFR, and other kinases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:01:40.021Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced non-small cell lung cancer"},{"name":"Medullary thyroid cancer"},{"name":"Soft tissue sarcoma"}]},"trialDetails":[{"nctId":"NCT03743129","phase":"PHASE2","title":"Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）","status":"COMPLETED","sponsor":"Anhui Shi, MD","startDate":"2019-04-12","conditions":"Non-Small Cell Lung Cancer Stage III","enrollment":90},{"nctId":"NCT04325763","phase":"PHASE3","title":"A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-05-27","conditions":"Stage III Non-small-cell Lung Cancer","enrollment":315},{"nctId":"NCT04234607","phase":"PHASE3","title":"A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-01","conditions":"Extensive Small Cell Lung Cancer","enrollment":738},{"nctId":"NCT04073550","phase":"PHASE3","title":"Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-10-31","conditions":"Small Cell Lung Cancer","enrollment":184},{"nctId":"NCT04073537","phase":"PHASE3","title":"Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-10-31","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":386}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Anlotinib(blank)","genericName":"Anlotinib(blank)","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anlotinib is a multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor growth by inhibiting VEGFR, FGFR, PDGFR, and other kinases. Used for Advanced non-small cell lung cancer, Medullary thyroid cancer, Soft tissue sarcoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}